150 related articles for article (PubMed ID: 10960842)
21. Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy.
van der Kwast TH; Labrie F; Tetu B
Hum Pathol; 1999 Dec; 30(12):1503-7. PubMed ID: 10667430
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant hormonal deprivation before radical prostatectomy.
Schulman CC; Sassine AM
Clin Invest Med; 1993 Dec; 16(6):523-31. PubMed ID: 7516836
[TBL] [Abstract][Full Text] [Related]
23. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study.
Têtu B; Srigley JR; Boivin JC; Dupont A; Monfette G; Pinault S; Labrie F
Am J Surg Pathol; 1991 Feb; 15(2):111-20. PubMed ID: 1989458
[TBL] [Abstract][Full Text] [Related]
24. Prostatic adenocarcinoma with glomeruloid features.
Pacelli A; Lopez-Beltran A; Egan AJ; Bostwick DG
Hum Pathol; 1998 May; 29(5):543-6. PubMed ID: 9596281
[TBL] [Abstract][Full Text] [Related]
25. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
[TBL] [Abstract][Full Text] [Related]
26. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status.
Hong H; Kao C; Jeng MH; Eble JN; Koch MO; Gardner TA; Zhang S; Li L; Pan CX; Hu Z; MacLennan GT; Cheng L
Cancer; 2004 Jul; 101(1):83-9. PubMed ID: 15221992
[TBL] [Abstract][Full Text] [Related]
27. BP1, a homeoprotein, is significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia.
Schwartz AM; Man YG; Rezaei MK; Simmens SJ; Berg PE
Mod Pathol; 2009 Jan; 22(1):1-6. PubMed ID: 18931648
[TBL] [Abstract][Full Text] [Related]
28. Expression of macrophage migration inhibitory factor in the human prostate.
Meyer-Siegler K; Fattor RA; Hudson PB
Diagn Mol Pathol; 1998 Feb; 7(1):44-50. PubMed ID: 9646034
[TBL] [Abstract][Full Text] [Related]
29. Inference network-based analyses of the histopathological effects of androgen deprivation on prostate cancer.
Montironi R; Santinelli A; Pomante R; Hamilton PW; Thompson D; Bartels PH
J Pathol; 1999 Mar; 187(4):462-8. PubMed ID: 10398107
[TBL] [Abstract][Full Text] [Related]
30. Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases.
Meyer-Siegler K; Hudson PB
Urology; 1996 Sep; 48(3):448-52. PubMed ID: 8804500
[TBL] [Abstract][Full Text] [Related]
31. Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment.
Guate JL; Escaf S; Menendez CL; del Valle M; Vega JA
Urol Int; 1997; 59(3):149-53. PubMed ID: 9428430
[TBL] [Abstract][Full Text] [Related]
32. [Neuroendocrine differentiation in adenocarcinoma of the prostate with progression of disease during hormonal treatment: a report of two cases].
Kosugi M; Hanawa Y; Momma T; Saito S; Hirose S
Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):521-4. PubMed ID: 12795167
[TBL] [Abstract][Full Text] [Related]
33. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer.
Witjes WP; Schulman CC; Debruyne FM
Urology; 1997 Mar; 49(3A Suppl):65-9. PubMed ID: 9123739
[TBL] [Abstract][Full Text] [Related]
34. Localized amyloidosis of the seminal vesicle. Possible association with hormonally treated prostatic adenocarcinoma.
Unger PD; Wang Q; Gordon RE; Stock R; Stone N
Arch Pathol Lab Med; 1997 Dec; 121(12):1265-8. PubMed ID: 9431316
[TBL] [Abstract][Full Text] [Related]
35. Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study.
Hampel OZ; Kattan MW; Yang G; Haidacher SJ; Saleh GY; Thompson TC; Wheeler TM; Marcelli M
J Urol; 1998 Jun; 159(6):2220-5. PubMed ID: 9598573
[TBL] [Abstract][Full Text] [Related]
36. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study.
Vailancourt L; Ttu B; Fradet Y; Dupont A; Gomez J; Cusan L; Suburu ER; Diamond P; Candas B; Labrie F
Am J Surg Pathol; 1996 Jan; 20(1):86-93. PubMed ID: 8540613
[TBL] [Abstract][Full Text] [Related]
37. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
[TBL] [Abstract][Full Text] [Related]
38. [The effect of combined endocrine therapy on prostate and testis].
Kong X; Zeng L; Xia T; Wang J; Mi P; Na Y; Xue Z; Pan B; Hao J; Gu F; Guo Y
Zhonghua Wai Ke Za Zhi; 1999 Apr; 37(4):231-4. PubMed ID: 11829828
[TBL] [Abstract][Full Text] [Related]
39. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
40. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Slovin SF
Nat Clin Pract Oncol; 2007 Sep; 4(9):551-4. PubMed ID: 17728713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
